BioCardia, Inc. filed a Form 8-K on November 20, 2026, disclosing that it received a written notice from Nasdaq on that same date stating the company is no longer in compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market.

Key Highlights

  • Deficiency identified: BioCardia's stockholders' equity was $835,000 as of September 30, 2026, below the $2.5 million minimum required under Nasdaq Listing Rule 5550(b)(1).
  • Response deadline: The company has until January 4, 2027 to submit a compliance plan to Nasdaq.
  • Potential extension: If Nasdaq accepts the plan, the company may receive an extension of up to 180 calendar days from November 20, 2026 to evidence compliance.
  • No immediate trading impact: According to the filing, the notice "has no immediate effect on the listing or trading of the Company's common stock," which continues to trade under the symbol BCDA on NASDAQ:BCDA.
  • Hearing option: If Nasdaq does not accept the plan, the company may request a hearing before a Nasdaq Hearings Panel.

BioCardia Discloses Stockholders' Equity Shortfall and Path to Compliance

BioCardia, Inc. (NASDAQ:BCDA), a Delaware-incorporated biopharmaceutical company headquartered in Sunnyvale, California, disclosed in its November 20, 2026 current report that it received a written deficiency notice from The Nasdaq Stock Market LLC on that date. The notice states that, based on the company's stockholders' equity of $835,000 as of September 30, 2026, BioCardia no longer meets the minimum stockholders' equity requirement of $2.5 million mandated by Nasdaq Listing Rule 5550(b)(1) for continued listing on the Nasdaq Capital Market.

According to the filing, the company has until January 4, 2027 to provide Nasdaq with a plan to regain compliance. If that plan is accepted, Nasdaq may grant an extension of up to 180 calendar days from November 20, 2026 for the company to demonstrate compliance. The filing notes that in evaluating the plan, Nasdaq will consider factors including "the likelihood that the plan will result in compliance with Nasdaq's continued listing criteria, the Company's past compliance history, the reasons for the Company's current non-compliance, other corporate events that may occur within Nasdaq's review period, the Company's overall financial condition and its public disclosures."

The company disclosed that it "intends to submit a plan to Nasdaq to regain compliance with the Nasdaq Listing Rules." The filing was signed by Peter Altman, Ph.D., President and Chief Executive Officer. The forward-looking statements contained in the filing are the company's own and are subject to its cautionary language, including the risk that there is "no assurance that the Company will be able to submit a plan or regain compliance during the required periods or otherwise in the future."

What Was Disclosed

BioCardia filed an 8-K on November 20, 2026 reporting receipt of a Nasdaq deficiency notice tied to a stockholders' equity of $835,000 as of September 30, 2026, which falls below the $2.5 million continued listing threshold under Nasdaq Listing Rule 5550(b)(1).